Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The most effective method to Beat Dental Tension and Guarantee Customary Exams - 2The Best Cell phone Brands for Tech Aficionados
- 3Australian State Triggers Emergency Powers Amid Fuel Crisis
- 4Picking the Right Home Machines: A Commonsense Aide
- 5Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application
- The Hybrid Volkswagen ID. ERA 9X Will Become the Brand’s New Flagship in China
- Manual for Vegetarian Protein Powder
- What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
- A Republican elected governor in California? It's not as far-fetched as it sounds.
- A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- 5 Morning Schedules That Stimulate Your Day
- A Time of Careful Eating: Individual Tests in Nourishment
- MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
- Fabricated statement about Malaysian national exam top scorers stokes racial sentiment
